Bristol-Myers: Opdivo Shows Encouraging Response, Survival Rates - Quick Facts

(RTTNews) - Bristol-Myers Squibb Company (BMY) announced data evaluating Opdivo (nivolumab) and Opdivo plus Yervoy (ipilimumab) in previously treated small cell lung cancer patients whose tumors were evaluable for tumor mutation burden, from the Phase 1/2 CheckMate -032 trial. The overall response rate with Opdivo was 21%, and more than double with the Opdivo plus Yervoy combination (46%). Overall survival rate with Opdivo at one year was 35%, and nearly double with the Opdivo plus Yervoy combination (62%).

Nick Botwood, development lead, thoracic cancers, Bristol-Myers Squibb, said, "Based on these exploratory data from CheckMate -032 in previously treated small cell lung cancer, and the growing scientific evidence for this biomarker, we continue to investigate tumor mutation burden to understand its relevance as a marker to potentially predict outcomes with immunotherapy. We are committed to our ongoing thoracic cancer development program, focused on identifying patients most likely to benefit from immunotherapy."